EXTL2

Across TCGA pan-cancer cohorts, EXTL2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated EXTL2 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher EXTL2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated EXTL2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where EXTL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.368	0.692	.001	87	view →
LUAD	OS	Tertile	II,III,IV	0.318	0.866	.017	8	view →
CCRCC	OS	Median	All	1.000	0.886	.022	3	view →
LSCC	DFS	Quartile	II,III,IV	0.892	0.190	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

EXTL2–PDAC (OS)

Open the PDAC breakdown →